ADA Technologies, Inc. (ADA) received a $149,121 grant from the National Cancer Institute* for research and development of nanotechnology imaging and sensing platforms for improved detection and diagnosis of cancer.
ADA’s research focuses on developing a nano-enabled sensing platform for analysis of biomolecules, such as cancer biomarkers, that is more sensitive than existing technologies. Analysis platforms that provide high sensitivity and high throughput are critical to cancer biomarker detection.
“Our research will provide the scientific and medical communities with a reliable, ready-to-use platform that is capable of detecting multiple biomolecules to facilitate cancer biomarker screening and improve cancer diagnosis,” said Xichun Zhou, ADA principal investigator.
ADA’s R&D efforts related to nanotechnology imaging and sensing platforms began in 2007.
*This project is wholly funded with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261200800061C.